Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > TCRR TCR2 Therapeutics > Detailed Quotes

TCRR TCR2 Therapeutics

1.720
-0.050-2.82%
Trading Session 10/07 11:45 ET
High
1.795
Open
1.760
Turnover
115.22K
Low
1.720
Pre Close
1.770
Volume
65.71K
Market Cap
66.40M
P/E(TTM)
Loss
52wk High
8.820
Shares
38.61M
P/E(Static)
Loss
52wk Low
1.598
Float Cap
43.38M
Bid/Ask %
-73.33%
Historical High
35.860
Shs Float
25.22M
Volume Ratio
0.72
Historical Low
1.598
Dividend TTM
--
Div Yield TTM
--
P/B
0.29
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.26%
Amplitude
4.24%
Avg Price
1.753
Lot Size
1
Float Cap
43.38M
Bid/Ask %
-73.33%
Historical High
35.860
Shs Float
25.22M
Volume Ratio
0.72
Historical Low
1.598
Dividend TTM
--
P/B
0.29
Dividend LFY
--
Turnover Ratio
0.26%
Amplitude
4.24%
Avg Price
1.753
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
CEO: Dr. Garry E. Menzel, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...